Abstract 1811: Evaluation of anti-CXCR2 small molecule inhibitors as novel chemotherapy targeting the Interleukin-8 pathway in colorectal cancer

Despite new and improved chemotherapy treatments for colorectal cancer (CRC) contributing to enhanced treatment response rates and patient prognosis, it has been suggested that an overwhelming 90% of metastatic CRC patients encounter treatment failure due to drug resistance. The Interleukin-8/CXCR2 pathway has been validated as a promising target for novel chemotherapy due to its overarching effects on various cell types within the tumor...